Discovery and optimization of chromenotriazolopyrimidines as potent inhibitors of the mouse double minute 2-tumor protein 53 protein-protein interaction

Journal of Medicinal Chemistry

Volumn 52, Issue 22, 2009, Pages 7044-7053

  Allen, John G ^a   Bourbeau, Matthew P ^a   Wohlhieter, G Erich ^a   Bartberger, Michael D ^a   Michelsen, Klaus ^a   Hungate, Randall ^a   Gadwood, Robert C ^b   Gaston, Rick D ^b   Evans, Bruce ^b   Mann, Larry W ^b,c   Matison, Michael E ^b   Schneider, Stephen ^a   Huang, Xin ^a   Yu, Dongyin ^a   Andrews, Paul S ^a   Reichelt, Andreas ^a   Long, Alexander M ^a   Yakowec, Peter ^a   Yang, Evelyn Y ^a   Lee, Tani Ann ^a,d   Oliner, Jonathan D ^a   more..

^a AMGEN INC   (United States)

^b Kalexsyn Inc   (United States)

^c PFIZER INC   (United States)

^d Prometheus Laboratories   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

(4 BROMOPHENYL) 1 (2 HYDROXYPHENYL)PROP 2 EN 1 ONE; 2 [7 (4 BHROMOPHENYL) 4,7 DIHYDRO[1,2,4]TRIAZOLO[1,5 A]PYRIMIDIN 5 YL]PHENOL; 2 [7 (4 BROMOPHENYL)4 METHYL 4,7 DIHYDRO[1,2,4]TRIAZOLO[1,5,A]PYRIMIDIN 5 YL]PHENOL; 6,7 BIS(4 BROMOPHENYL) 7,12 DIHYDRO 6H CHROMENO[4,3 D] [1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; 6,7 BIS(4 BROMOPHENYL) 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; 7 (4 BROMOPHENYL) 5 (2 [[TERT BUTYL(DIMETHYL)SILYL]OXY]PHENYL) 4 METHYL 4,7 DIHYDRO[1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; 7 (4 BROMOPHENYL) 5 (2 [[TERT BUTYL(DIMETHYL)SILYL]OXY]PHENYL) 4,7 DIHYDRO[1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; ANTINEOPLASTIC AGENT; PROTEIN MDM2; PROTEIN P53; PYRIMIDINE DERIVATIVE; SYN 4 [6 (4 BROMOPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDIN 7 YL]BENZONITRILE; SYN 4 [6 (4 BROMOPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6 (4 BROMOPHENYL) 12 METHYL 7 (4 METHYLPHENYL) 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6 (4 BROMOPHENYL) 7 (4 FLUOROPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 BROMOPHENYL) 1 ETHOXY 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 BROMOPHENYL) 1 FLUORO 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 BROMOPHENYL) 12 METHYL 1 (METHYLOXY) 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 BROMOPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 BROMOPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3,D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4 FLUOROPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 6,7 BIS(4CHLOROPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 7 (4 BROMOPHENYL) 12 METHYL 6 (4 METHYLPHENYL) 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 7 (4 BROMOPHENYL) 12 METHYL 6 (4 PROP 1 YN 1 YLPHENYL) 7,12 DIHYDRO 6H CHROMENO[4,3,D][1,2,4]TRIAZOLO[1,5,A]PYRIMIDINE; SYN 7 (4 BROMOPHENYL) 6 (4 CHLOROPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 7 (4 BROMOPHENYL) 6 (4 ETHYLPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 7 (4 BROMOPHENYL) 6 (4 ETHYNYLPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; SYN 7 BIS(4 BROMOPHENYL) 6 (4 FLUOROPHENYL) 12 METHYL 7,12 DIHYDRO 6H CHROMENO[4,3 D][1,2,4]TRIAZOLO[1,5 A]PYRIMIDINE; TUMOR PROTEIN; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANIMAL EXPERIMENT; APOPTOSIS; ARTICLE; CARBON NUCLEAR MAGNETIC RESONANCE; CELL CYCLE REGULATION; CELL PROLIFERATION; CELL STRAIN HCT116; CRYSTALLIZATION; DRUG STRUCTURE; HIGH THROUGHPUT SCREENING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTEIN PROTEIN INTERACTION; PROTON NUCLEAR MAGNETIC RESONANCE; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

APOPTOSIS; CELL PROLIFERATION; DRUG DISCOVERY; HCT116 CELLS; HUMANS; INHIBITORY CONCENTRATION 50; MODELS, MOLECULAR; MOLECULAR CONFORMATION; PROTEIN BINDING; PROTO-ONCOGENE PROTEINS C-MDM2; PYRIMIDINES; STEREOISOMERISM; STRUCTURE-ACTIVITY RELATIONSHIP; TUMOR SUPPRESSOR PROTEIN P53;

EID: 70949084205     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm900681h     Document Type: Article

References (53)

1. (a) Fridman, J. S.; Lowe, S. W. Control of apoptosis by p53. Oncogene 2003, 22, 9030-9040.
2. (b) Vazquez, A.; Bond, E. E.; Levine, A. J.; Bond, G. L. The genetics of the p53 pathway, apoptosis and cancer therapy. Nat. Rev. Drug Discovery 2008, 7, 979-987.
3. (a) Jones, S. N.; Sands, A. T.; Hancock, A. R.; Vogel, H.; Donehower, L. A.; Linke, S. P.; Wahl, G. M.; Bradley, A. The tumorigenic potential and cell growth characteristics of p53-deficient cells are equivalent in the presence or absence of MDM2. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 14106-14111.
4. (b) Iwakuma, T.; Lozano, G. Crippling p53 activities via knock-in mutations in mouse models. Oncogene 2007, 26, 2177-2184. (Pubitemid 46536640)
5. (c) Lozano, G.; Zambetti, G. P. What have animal models taught us about the p53 pathway? J. Pathol. 2005, 205, 206-220. (Pubitemid 40227992)
6. (a) Johnston, J. B.; Daeninck, P.; Verburg, L.; Lee, K.; Williams, G.; Israels, L. G.; Mowat, M. R. A.; Begleiter, A. p53, MDM2, BAX and BCL2 and drug resistance in chronic lymphocytic leukemia. Leuk. Lymphoma 1997, 26, 435-449.
7. (b) Buttitta, F.; Marchetti, A.; Gadducci, A.; Pellegrini, S.; Morganti, M.; Carnicelli, V.; Cosio, S.; Gagetti, O.; Genazzani, A. R.; Bevilacqua, G. p53 alterations are predictive of chemoresistance and aggressiveness in ovarian carcinomas: a molecular and immunohistochemical study. Br. J. Cancer 1997, 75, 230-235.
8. (c) Harada, T.; Ogura, S.; Yamazaki, K.; Kinoshita, I.; Itoh, T.; Isobe, H.; Yamashiro, K.; Dosaka-Akita, H.; Nishimura, M. Predictive value of expression of p53, Bcl-2 and lung resistance-related protein for response to chemotherapy in non-small cell lung cancers. Cancer Sci. 2003, 94, 394-399.
9. (d) Yamazaki, Y.; Chiba, I.; Hirai, A.; Ken-ichi, N.; Haruhiko, K.; Kanchu, T.; Yasunori, T.; Tadashi, I.; Takao, K.; Hiroshi, F. Radioresistance in oral squamous cell carcinoma with p53 DNA contact mutation. Am. J. Clin. Oncol. 2003, 26, e124-e129.
10. (e) Petitjean, A.; Achatz, M. I.; Borresen-Dale, A. L.; Hainaut, P.; Olivier, M. TP53 mutations in human cancers: Functional selection and impact on cancer prognosis and outcomes. Oncogene 2007, 26, 2157-2165. (Pubitemid 46536647)
11. Soussi, T.; Dehouche, K.; Beroud, C. p53 web-site and analysis of p53 gene mutations in human cancer: forging a link between epidemiology and carcinogenesis. Hum. Mutat. 2000, 15, 105-113.
12. (a) Eymin, B.; Gazzeri, S.; Brambilla, C.; Brambilla, E. MDM2 overexpression and p14ARF inactivation are two mutually exclusive events in primary human lung tumors. Oncogene 2002, 21, 2750-2761. (Pubitemid 34478333)
13. (b) Polsky, D.; Bastian, B. C.; Hazan, C.; Melzer, K.; Pack, J.; Houghton, A.; Busam, K.; Cordon-Cardo, C.; Osam, I. HDM2 protein overexpression, but not gene amplification, is related to tumorigenesis of cutaneous melanoma. Cancer Res. 2001, 61, 7642-7646.
14. Momand, J.; Mung, D.; Wilczynski, S.; Niland, J. The MDM2 gene amplification database. Nucleic Acids Res. 1998, 26, 3453-3459.
15. Michael, D.; Oren, M. The p53-MDM2 module and the ubiquitin system. Semin. Cancer Biol. 2003, 13, 49-58.
16. Oliner, J. D.; Kinzler, K. W.; Meltzer, P. S.; George, D.; Vogelstein, B. Amplification of a gene encoding a p53-associated protein in human sarcomas. Nature 1992, 358, 80-83.
17. (a) Haupt, Y.; Maya, R.; Kaza, A.; Oren, M. MDM2 promotes the rapid degradation of p53. Nature 1997, 387, 296-299. (Pubitemid 27220766)
18. (b) Kubbutat, M. H. G.; Jones, S. N.; Vousden, K. H. Regulation of p53 stability by MDM2. Nature 1997, 387, 299-303.
19. (c) Midgley, C. A.; Lane, D. P. p53 protein stability in tumor cells is not determined by mutation but is dependent on MDM2 binding. Oncogene 1997, 15, 1179-1189. (Pubitemid 27429621)
20. (a) Wu, X.; Bayle, J. H.; Olson, D.; Levine, A. J. The p53-MDM2 autoregulatory feedback loop. Genes Dev. 1993, 7, 1126-1131.
21. (b) Oliner, J. D.; Pietenpol, J. A.; Thiagalingam, S.; Gyuris, J.; Kinzler, K. W.; Vogelstein, B. Oncoprotein MDM2 conceals the activation domain of tumor suppressor p53. Nature 1993, 362, 857-860. (Pubitemid 23132165)
22. (c) Picksley, S.; Lane, D. The p53-MDM2 autoregulatory feedback loop: A paradigm for the regulation of growth control by p53? BioEssays 1993, 15, 689-690.
23. (d) Ashcroft, M.; Vousden, K. Regulation of p53 stability. Oncogene 1999, 18, 7637-7643.
24. (a) Lane, D. Exploiting the p53 pathway for cancer diagnosis and therapy. Br. J. Cancer 1999, 80 (Suppl 1), 1-5.
25. (b) Chene, P. Inhibiting the p53-MDM2 interaction: an important target for cancer therapy. Nature Rev. Cancer 2003, 3, 102-109. (Pubitemid 37328877)
26. (c) Bottger, A.; Bottger, V.; Sparks, A.; Liu, W. -L.; Howard, S. F.; Lane, D. P. Design of a synthetic MDM2-binding mini protein that activates the p53 response in vivo. Curr. Biol. 1997, 7, 860-869.
27. Carvajal, D.; Tovar, C.; Yang, H.; Vu, B. T.; Heimbrook, D. C.; Vassilev, L. T. Activation of p53 by MDM2 antagonists can protect proliferating cells from mitotic inhibitors. Cancer Res. 2005, 65, 1918-1924.
28. (a) Jones, S.; Thornton, J. M. Principles of protein-protein interactions. Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 13-20.
29. (b) Fry, D. C. Protein-protein interactions as targets for small molecule drug discovery. Biopolymers 2006, 84, 535-552.
30. (c) Fry, D. C.; Vassilev, L. T. Targeting protein-protein interactions for cancer therapy. J. Mol. Med. 2005, 83, 955-963.
31. (a) Clackson, T.; Wells, J. A. A hot spot of binding energy in a hormone-receptor interface. Science 1995, 267, 383-386.
32. (b) Moreira, I. S.; Fernandes, P. A.; Ramos, M. J. Hot spots - a review of the protein-protein interface determinant amino-acid residues. Proteins 2007, 68, 803-812.
33. (a) Vassilev, L. T.; Vu, B. T.; Graves, B.; Carvajal, D.; Podlaski, F.; Filipovic, Z.; Kong, N.; Kammlott, U.; Lukacs, C.; Klein, C.; Fotouhi, N.; Liu, E. A. In vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 2004, 303, 844-848.
34. (b) Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Gupta, V.; Lattanze, J.; Ramachandren, K.; Carver, T. E.; Petrella, E. C.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Lu, T. 1,4-Benzodiazepine-2,5- diones as small molecule antagonists of the HDM2-p53 interaction: discovery and SAR. Bioorg. Med. Chem. Lett. 2005, 15, 765-770.
35. (c) Parks, D. J.; LaFrance, L. V.; Calvo, R. R.; Milkiewicz, K. L.; Maruga'n, J. J.; Raboisson, P.; Schubert, C.; Knoblish, H. K.; Zhao, S; Franks, C. F.; Lattanze, J.; Carver, T. E.; Cummings, M. D.; Maguire, D.; Grasberger, B. L.; Maroney, A. C.; Lu, T. Enhanced pharmacokinetic properties of 1,4-benzodiazepine-2,5-dione antagonists of the HDM2-p53 protein-protein interaction through structure-based drug design. Bioorg. Med. Chem. Lett. 2006, 16, 3310-3314.
36. (d) Ding, K.; Lu, Y.; Nikolovska-Coleska, Z.; Wang, G.; Qiu, S.; Shangary, S.; Gao, W.; Qin, D.; Stuckey, J.; Krajewski, K.; Roller, P. P.; Wang, S. Structure-based design of spiro-oxindoles as potent, specific small-molecule inhibitors of the MDM2-p53 interaction. J. Med. Chem. 2006, 49, 3432-3435.
37. (e) Hardcastle, I. R.; Ahmed, S. U.; Atkins, H.; Calvert, A. H.; Curtin, N. J.; Farnie, G.; Golding, B. T.; Griffin, R. J.; Guyenne, S.; Hutton, C.; Kallblad, P.; Kemp, S. J.; Kitching, M. S.; Newell, D. R.; Norbedo, S.; Northen, J. S.; Reid, R. J.; Saravanan, K.; Willems, H. M. G.; Lunec, J. Isoindolinone-based inhibitors of the MDM2-p53 proteinprotein interaction. Bioorg. Med. Chem. Lett. 2005, 15, 1515-1520.
38. (a) Kussie, P. H.; Gorina, S.; Marcchal, V.; Elenbaas, B.; Moreau, J.; Levine, A. J.; Pavletich, N. P. Structure of the MDM2 oncoprotein bound to the p53 tumor suppressor transactivation domain. Science 1996, 274, 948-953.
39. (b) Garcia-Echeverria, C.; Chene, P.; Blommers, M. J. J.; Furet, P. Discovery of potent antagonists of the interaction between human double minute 2 and tumor suppressor p53. J. Med. Chem. 2000, 43, 3205-3208.
40. (a) Hu, C.-Q.; Hu, Y.-Z. Small molecule inhibitors of the p53-MDM2. Curr. Med. Chem. 2008, 15, 1720-1730.
41. (b) Patel, S.; Player, M. R. Small-molecule inhibitors of the p53-HDM2 interaction for the treatment of cancer. Expert Opin. Invest. Drugs 2008, 17, 1865-1882.
42. HTRF data was reported as the mean ± SD at 95% confidence, n ≥ 4.
43. 50)/NHA: Hopkins, A. L.; Groom, C. R.; Alex, A. Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 2004, 9, 430-431.
44. A survey of 13 small molecule inhibitors of 7 protein-protein interaction targets had an average LE = 0.24 kcal/mol per non-hydrogen atom: Wells, J. A.; McClendon, C. L. Reaching for high-hanging fruit in drug discovery at protein-protein interfaces. Nature 2007, 450, 1001-1009.
45. (a) Desenko, S. M.; Orlov, V. D.; Getmanskii, N. V.; Komykhov, S. A. Imine-enamine tautomerization of dihydroazolopyrimidines 4. Synthesis and tautomerization of 5-(2-hydroxyphenyl)-dihydro-1,2,4-triazolo[1,5-a]pyrimidines. Chem. Heterocycl. Compd. 1993, 29, 1160-1162.
46. (b) Desenko, S. M.; Orlov, N. V.; Getmanskii, N. V.; Komykhov, S. A.; Paponov, B. V.; Kovalevskii, A. Yu.; Shishkin, O. V.; Struchkov, Yu. T. Synthesis and structure of 3,7-dihydro-2H-1,2,4-triazolo-[1′,5′- a′]tripyrimido[4,5-d]benzo[b]pyrans. Chem. Heterocycl. Compd. 1996, 32, 215-220.
47. 2 arrest after DNA damage. Science 1998, 282, 1497-1501.
48. 1 arrest in human cancer cells. Cancer Res. 1995, 55, 5187-5190.
49. (a) Stephens, P. J.; Lowe, M. A. Vibrational circular dichroism. Annu. Rev. Phys. Chem. 1985, 36, 213-241.
50. (b) Polavarapu, P. L.; Zhao, C. Vibrational circular dichroism: a new spectroscopic tool for biomolecular structural determination. Fresenius' J. Anal. Chem. 2000, 366, 727-734.
51. (c) Stephens, P. J.; Devlin, F. J. Determination of the structure of chiral molecules using ab initio vibrational circular dichroism spectroscopy. Chirality 2000, 12, 172-179.
52. (d) Freedman, T. B.; Cao, X.; Dukor, R. K.; Nafie, L. A. Absolute configuration determination of chiral molecules in the solution state using vibrational circular dichroism. Chirality 2003, 15, 743-758. (Pubitemid 37356644)
53. (e) Devlin, F. J.; Stephens, P. J.; Cheeseman, J. R.; Frisch, M. Ab initio prediction of vibrational absorption and circular dichroism spectra of chiral natural products using density functional theory: Camphor and fenchone. J. Phys. Chem. A 1997, 101, 6322-6333.